XJPX
4540
Market cap1.77bUSD
Oct 09, Last price
3,772.00JPY
1D
0.72%
1Q
-1.26%
Jan 2017
17.14%
Name
Tsumura & Co
Chart & performance
P/E
10.00
P/S
1.46
EPS
377.18
Div yield, %
3.63%
Shrs. gr., 5y
-0.47%
Rev. gr., 5y
8.03%
Revenues
192.62b
+6.36%
Net income
28.12b
-13.29%
CFO
24.72b
-26.92%
Dividend
Mar 30, 202779 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extract intermediates and granular Kampo preparations. Its operations are comprehensive, encompassing the full supply chain: from the careful acquisition, selection, processing, and warehousing of raw herbal materials and crude drug components for decoctions, to the manufacturing of powdered Kampo extracts and traditional Chinese medicines. Additionally, Tsumura & Co. is engaged in the sale of both pharmaceutical goods and food products.
Key people
Kaoru Kobayashi
Chief Financial Officer, Senior Director of Business · since 2025
Kei Sugii
Co-Chief Operating Officer, Director · since 2022
Koin Toda
Co-Chief Operating Officer · since 2021
Koji Endo
Executive Officer, Manager of Tsumara Academy · since 2023
Akihito Konda
Executive Officer, Chief Director of Research & Development · since 2024
Shoichi Kumagai
Executive Officer, Chief Director of Production · since 2022
Kazushige Mizoguchi
Executive Officer, Chief Director of Reliability Assurance · since 2024
Yasushi Nakagawa
Executive Officer, Chief Director of Healthcare · since 2025
Koji Shiseki
Executive Officer, Director of Legal Affairs · since 2024
Yoshiharu Watanabe
Executive Officer · since 2023
Toshio Yamaoka
Executive Officer, Chief Director of Pharmaceutical Sales · since 2025
Liqing Zhang
Executive Officer · since 2022
Muneki Handa
Chief Financial Officer, Director · since 2021
Terukazu Kato
President, Chief Executive Officer, Representative Director · since 2019
Tomihiro Nagafuchi
Director · since 2023
Mariko Eguchi
Independent Director · since 2025
Hiroshi Miyake
Independent Director · since 2018
Akemi Mochizuki
Independent Director · since 2019
Tadashi Okada
Independent Director · since 2020
Chieko Tsuchiya
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||